Abstracts submission
AUTHORS GUIDELINES
Acceptance notifications for oral ond poster presentations have been sent by email. Please note that for abstracts submitted under the topic 14 - Comorbidities in Psoriasis, the acceptance will be confirmed at the beginning of April.
For more information regarding the guidelines for your poster or oral presentation, please click here.
The abstract submission is now closed.
CALL FOR ABSTRACTS
The Organizers invite scientists, clinicians and researchers to submit an abstract to the forthcoming 2nd International Congress on Psoriasis, to be held in Paris, Palais des Congrès, 21-24 June 2007.
The DEADLINE for ABSTRACT submission is:
February 19, 2007
GUIDELINES FOR ABSTRACTS
All abstracts must be written in English.
Selected abstracts will be presented as posters and the best scored posters will be presented during the workshop sessions.
Remember that ONLY electronically submitted abstracts will be considered.
Abstracts received after the deadline cannot be accepted and will therefore not be considered for the program or for publication.
The selected abstracts will be displayed as posters and the best scored posters will be presented (6 minutes) during the workshop sessions. A preference for poster display can be indicated although the Scientific Committee will make the final decision as to how the abstract will be presented.
Abstracts accepted for presentation will be published in the Congress Abstract Book. Abstracts must contain work that has not been previously presented at any national or international meeting before February 1, 2007.
Abstracts are considered by the Committee without knowledge of their source. Acceptance or rejection of an abstract is based on the average grade awarded by the reviewers. The abstract should be presented in such a way that the contribution of the research to advance knowledge can be assessed. The authors’ conclusions should be clearly stated. General statements such as “the significance of these findings will be discussed” will be regarded unfavourably and will generally lead to exclusion of the abstracts. Initials and abbreviations which are not in common use should be avoided unless they are essential.
TOPICS
- Scoring and monitoring the severity of the disease
- Management of severe clinical manifestations
- Psoriasis in children and pregnancy
- Difficult to treat localisations
- Topical treatment: what to choose and how to use
- Epidemiology and regional specificity
- Systemic therapies: what to choose and how to use (Retinoids, cyclosporine, fumaric acid)
- Risk management and treatment optimisation: combination and rational strategies
- Phototherapies: what to choose and how to use
- Systemic therapies: what to choose and how to use (methotrexate, azathioprin, hydroxyurea)
- Alternative treatment
- Biologics
- Extracutaneous manifestations in psoriasis
- Comorbidities in Psoriasis